The first 60 days: Urethral cancer
Urethral cancer grows in the tube that carries urine out of the body, with fewer than one case per million people a year. With no randomised trials, it is treated by borrowing from bladder, anal or vulvar cancer depending on cell type and location; chemotherapy with radiotherapy before or instead of surgery lets more patients keep their organs. Below, week by week, is what OnCo's record of Urethral cancer says about the first two months: the order is typical, the timing is yours to ask about. Sections appear only where the record has something to say. Orientation, not medical advice.
What happens now
Staging tests establish exactly what and where the cancer is. Everything else follows from the answers.
Ask which of these were tested and what the results were; see the report reader for what each value means.
These specialties appear in the standard of care for this cancer. In most centres they meet weekly as a tumour board to agree each plan; you can ask when yours was discussed and what was decided.
- PathologistNamed in the standard of care for: Proximal or locally advanced, Metastatic.
- SurgeonNamed in the standard of care for: Distal, localised, Proximal or locally advanced.
- Medical oncologistNamed in the standard of care for: Distal, localised, Proximal or locally advanced, Metastatic.
- Clinical oncologist (radiotherapy)Named in the standard of care for: Distal, localised, Proximal or locally advanced.
A second opinion from a centre that treats many similar cases is normal, not rude; the standard of care tells you what to compare it against.
Each row is a setting from the standard of care, in the order it usually arises. Not all will apply to you; your stage and biomarkers decide which do. The guideline grade, where recorded, says how strong the evidence is.
Organ-sparing surgery (distal urethrectomy, partial penectomy) or radiotherapy including brachytherapy.
- 2.Proximal or locally advancedNCCN category Category 2A (in Bladder Cancer guideline, primary carcinoma of the urethra section), NCCN Guidelines: Bladder Cancer
Neoadjuvant platinum-based chemotherapy (or chemoradiation for squamous histology) followed by surgery; definitive chemoradiation as organ-preserving alternative.
Treat by histology: urothelial-type regimens (enfortumab vedotin plus pembrolizumab, gemcitabine-cisplatin) or squamous regimens; clinical trials.
Generated from this cancer's standard of care, biomarkers and open problems. Take the group that matches where you are. To tick, add your own and print, open the one-page appointment sheet.
Newly diagnosed
- What is my exact diagnosis, stage, and grade, and which tests established them?Everything else follows from an accurate stage and subtype.
- Which biomarkers have been tested on my tumour (for example Histology and site, Clinical and MRI stage, nodal status, HPV / p16 in squamous tumours, PD-L1 and FGFR3 in urothelial histology, Urine cytology and urethroscopy findings), and what were the results?These results decide eligibility for targeted therapy, immunotherapy, and trials.
- Which subtype is my cancer, and does that change the recommended treatment?Recognised subtypes for this cancer include Urothelial carcinoma, Squamous cell carcinoma, Adenocarcinoma.
- Is germline (inherited) genetic testing recommended for me or my family?Inherited variants can change treatment and matter for relatives.
Distal, localised
- For my situation (distal, localised), which of the standard options do you recommend and why?Guideline options include: Organ-sparing surgery (distal urethrectomy, partial penectomy) or radiotherapy including brachytherapy.
Proximal or locally advanced
- For my situation (proximal or locally advanced), which of the standard options do you recommend and why?Guideline options include: Neoadjuvant platinum-based chemotherapy (or chemoradiation for squamous histology) followed by surgery; definitive chemoradiation as organ-preserving alternative.
- Am I a candidate for Cisplatin, Gemcitabine + cisplatin, Fluorouracil (5-FU) or related drugs, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
Metastatic
- For my situation (metastatic), which of the standard options do you recommend and why?Guideline options include: Treat by histology: urothelial-type regimens (enfortumab vedotin plus pembrolizumab, gemcitabine-cisplatin) or squamous regimens; clinical trials.
- Am I a candidate for Enfortumab vedotin, Pembrolizumab, Gemcitabine + cisplatin, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
Any stage
- Are there clinical trials I could join, for example of Enfortumab vedotin, Pembrolizumab?Trials are how the next standard of care is set; asking early keeps options open.
- Would a second opinion at a high-volume centre change anything, and can you help arrange it?Rare or high-stakes decisions benefit from a centre that treats many similar patients.
- What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?Supportive care improves quality of life and helps patients complete treatment.
- I read that “No prospective trials; international registries and inclusion in urothelial and HPV-squamous basket trials are the response”. How does that affect my plan?Open problems are where trials and second opinions matter most.
- I read that “Late diagnosis mimicking benign stricture; urethroscopy for unexplained stricture or bleeding is the practical fix”. How does that affect my plan?Open problems are where trials and second opinions matter most.
Much of what helps in the first weeks is free if you know to ask: testing, helplines, rides and lodging, second opinions, trial travel.
- Urethral cancer: the full pageUrethral cancer grows in the tube that carries urine out of the body, with fewer than one case per million people a year. With no randomised trials, it is treated by borrowing from bladder, anal or vulvar cancer depending on cell type and location; chemotherapy with radiotherapy before or instead of surgery lets more patients keep their organs.
- One-page appointment sheetYour questions, the words you may hear, what to bring, and space for the answers. Print it.
- Treatment sequencingWhich treatment tends to follow which, line by line.
- NavigatorStandard of care for your stage, what you have tried, and trials near you.
- FGFR3 alterations (bladder cancer): FGFR3 is a growth-receptor gene mutated or fused in about a fifth of advanced bladder cancers and most low-grade early ones.
- HPV-positive (p16) head and neck cancer: Throat cancers caused by the human papillomavirus, identified by a p16 stain.
- Chemoradiation (chemoradiotherapy, CRT): Radiotherapy given at the same time as chemotherapy, which sensitises the cancer to radiation.
Every term links to the glossary.